Price
No data yet.
Social Signal Score
Analyst Ratings
6 analystsRevenue
$1.11MAnalyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Faraz Ali
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 70
- Beta
- 2.78
- Country
- US
- Piotroski score
- 3 / 9 (Weak)
- Altman Z-score
- -9.71
Financials
Revenue
$1.11M+393.3%Net Income
$-43.39MEBITDA
$-41.69MFree Cash Flow
$-22.96MEPS (diluted)
$-0.20Shares Outstanding (diluted)
217.57M+699.9%Operating Expenses
$22.01MCash & Debt
$78.08MReturn of Capital
$0.00Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-90.60M | $-0.59 |
| 2024 | $0.00 | $-111.13M | $-1.31 |
| 2023 | $0.00 | $-124.08M | $-1.68 |
| 2022 | $0.00 | $-123.67M | $-2.76 |
| 2021 | $0.00 | $-72.72M | $-1.69 |
| 2020 | $0.00 | $-38.40M | $-0.93 |
| 2019 | $0.00 | $-25.78M | $-0.95 |
Valuation
TNYAhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
100-16.67%Social Signal Score
Mentions (4)
- Newsglobenewswire.com·22d ago·Neutral
Tenaya Therapeutics Granted U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for TN-401 for the Treatment of PKP2-Associated Arrhythmogenic Right Ventricular Cardiomyopathy RMAT Designation Supported by Positive Interim Data from RIDGE™-1 Phase 1b/2 Clinical Trial of TN-401 which Demonstrated Reduced Arrhythmia Burden
View source ↗ - Newsglobenewswire.com·32d ago·Negative
…apeutics to Participate in Upcoming September Investor Conferences SOUTH SAN FRANCISCO, Calif., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced that Company management will host investor meetings at the upcoming H.C. Wainwright 28th Annual Global Investment Conference on Monday, Sept…
View source ↗ - Newsmarketbeat.com·49d ago·Neutral
Tenaya Therapeutics Eyes Q4 Updates for Cardiac Gene Therapies, TN-301 Tenaya Therapeutics NASDAQ: TNYA expects to provide regulatory and development updates in the fourth quarter for its two cardiac gene therapy programs and its small-molecule candidate TN-301, Chief Financial Officer Eric Hyllengren said during a Canaccord discussion.
View source ↗ - Newsseekingalpha.com·53d ago·Positive
Tenaya Therapeutics, Inc. (TNYA) Presents at Canaccord Genuity's 46th Annual Growth Conference Transcript Tenaya Therapeutics, Inc. (TNYA) Presents at Canaccord Genuity's 46th Annual Growth Conference Transcript
View source ↗
Earnings
Wed, Nov 11(in 5 weeks)
Consensus estimate $-0.10 per share
Typical surprise +7.7% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Aug 5$-0.20 vs $-0.07miss
- Wed, May 6$-0.09 vs $-0.09beat
- Wed, Mar 11$-0.12 vs $-0.13beat
- Mon, Nov 10$-0.12 vs $-0.15beat
- Wed, Aug 6$-0.14 vs $-0.20beat
- Wed, May 7$-0.24 vs $-0.18miss
Estimates and results for TNYA via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by TNYA officers and directors.
- Bought
- $132.1m
- Sold
- $5.1m
6 trades
54 trades
- Ali Farazsold
- Ali Farazsold
- Ali Farazsold
- Ali Farazsold
- Tingley Whittemoresold
- Tingley Whittemoresold
- Tingley Whittemoresold
- Tingley Whittemoresold
40 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in TNYA.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.